Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling
Dyne Therapeutics stock sinks on Novartis' failed Phase 3 myotonic dystrophy study, even as Dyne prepares new trial data presentations.
Stocks · News reference
Dyne Therapeutics To Demonstrate Additional One-Year Results From Phase 1/2 ACHIEVE Study Of Zeleciment Basivarsen For DM1 At Annual International Congress Of World Muscle Society
Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it will present
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings
Dyne Therapeutics shares are trading lower. The company announced it will present additional one-year Phase 1/2 ACHIEVE trial data for zeleciment basivarsen in DM1 at the 31st WMS Congress and the 2026 AANEM Annual Meeting.
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endpoint; other biotech stocks also declined.